The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Acute promyelocytic leukemia: where did we start, where are we now, and the future
Open accessAbstract
Historically, acute promyelocytic leukemia (APL) was considered to be one of the most fatal forms of acute leukemia with poor outcomes before the introduction of the vitamin A derivative all-trans retinoic acid (ATRA). With considerable advances in therapy, including the introduction of ATRA initially as a single agent and then in combination with anthracyclines, and more recently by development of arsenic trioxide (ATO)-containing regimens, APL is now characterized by complete remission rates of 90% and cure rates of ∼80%, even higher among low-risk patients. Furthermore, with ATRA–ATO combinations, chemotherapy may safely be omitted in low-risk patients. The disease is now considered to be the most curable subtype of acute myeloid leukemia (AML) in adults. Nevertheless, APL remains associated with a significant incidence of early death related to the characteristic bleeding diathesis. Early death, rather than resistant disease so common in all other subtypes of AML, has emerged as the major cause of treatment failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
Huang, M., Ye, Y., Chen, Sr., Chai, Jr., Lu, J., Zhoa, L., Gu, L., & Wang, Z. (1988) · Blood · doi:10.1182/blood.v72.2.567.567 · Cited by 2,445
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300874 · Cited by 1,611
Acute promyelocytic leukemia: from highly fatal to highly curable
Wang, Z.-Y., & Chen, Z. (2008) · Blood · doi:10.1182/blood-2007-07-102798 · Cited by 1,277
Castaigne, S., Chomienne, C., Daniel, M., Ballerini, P., Berger, R., Fenaux, P., & Degos, L. (1990) · Blood · doi:10.1182/blood.v76.9.1704.1704 · Cited by 1,184
All-trans-Retinoic Acid in Acute Promyelocytic Leukemia
Tallman, M. S., Andersen, J. W., Schiffer, C. A., Appelbaum, F. R., Feusner, J. H., Ogden, A., Shepherd, L., Willman, C., Bloomfield, C. D., Rowe, J. M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371501 · Cited by 1,073
Self-citationCastaigne, S., Pautas, C., Terré, C., Raffoux, E., Bordessoule, D., Bastie, J.-N., Legrand, O., Thomas, X., Turlure, P., Reman, O., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60485-1 · Cited by 1,015
Sanz, M. A., Grimwade, D., Tallman, M. S., Lowenberg, B., Fenaux, P., Estey, E. H., Naoe, T., Lengfelder, E., Büchner, T., Döhner, H., et al. (2009) · Blood · doi:10.1182/blood-2008-04-150250 · Cited by 947
Self-citationFenaux, P., Chastang, C., Chevret, S., Sanz, M., Dombret, H., Archimbaud, E., Fey, M., Rayon, C., Huguet, F., Sotto, J.-J., et al. (1999) · Blood · doi:10.1182/blood.v94.4.1192 · Cited by 754
Sanz, M. Á., Coco, F. L., Martı́n, G., Avvisati, G., Rayón, C., Barbui, T., Diaz‐Mediavilla, J., Fioritoni, G., González, J. D., Liso, V., et al. (2000) · PubMed · Cited by 631
Niu, C., Yan, H., Yu, T., Sun, H.-P., Liu, J.-X., Li, X.-S., Wu, W., Zhang, F.-Q., Chen, Y., Zhou, L., et al. (1999) · Blood · doi:10.1182/blood.v94.10.3315.422k16_3315_3324 · Cited by 625
Shen, Z.-X., Shi, Z.-Z., Fang, J., Gu, B.-W., Li, J.-M., Zhu, Y.-M., Shi, J.-Y., Zheng, P.-Z., Yan, H., Liu, Y.-F., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400053101 · Cited by 583
Fenaux, P., Le Deley, M., Castaigne, S., Archimbaud, E., Chomienne, C., Link, H., Guerci, A., Duarte, M., Daniel, M., & Bowen, D. (1993) · Blood · doi:10.1182/blood.v82.11.3241.3241 · Cited by 516
Mandelli, F., Diverio, D., Avvisati, G., Luciano, A., Barbui, T., Bernasconi, C., Broccia, G., Cerri, R., Falda, M., Fioritoni, G., et al. (1997) · PubMed · doi:10.1182/blood.v90.3.1014 · Cited by 474
Evidence for a 15; 17 translocation in every patient with acute promyelocytic leukemia
Larson, R. A., Kondo, K., Vardiman, J. W., Butler, A. E., Golomb, H. M., & Rowley, J. D. (1984) · The American Journal of Medicine · doi:10.1016/0002-9343(84)90994-x · Cited by 417
Sanz, M. Á., Martı́n, G., Rayón, C., Esteve, J., González, M., Diaz‐Mediavilla, J., Bolufer, P., Barragán, E., Terol, M. J., González, J. D., et al. (1999) · PubMed · Cited by 409
Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid
Park, J. H., Qiao, B., Panageas, K. S., Schymura, M. J., Jurcic, J. G., Rosenblat, T. L., Altman, J. K., Douer, D., Rowe, J. M., & Tallman, M. S. (2011) · Blood · doi:10.1182/blood-2011-04-346437 · Cited by 409
Self-citationChen, Z., Xue, Y., Zhang, R., Tao, R., Xia, X., Li, C., Wang, W., Zu, W., Yao, X., & Ling, B. (1991) · Blood · doi:10.1182/blood.v78.6.1413.1413 · Cited by 399
Estey, E., Garcia-Manero, G., Ferrajoli, A., Faderl, S., Verstovsek, S., Jones, D., & Kantarjian, H. (2006) · Blood · doi:10.1182/blood-2005-10-4006 · Cited by 384
Powell, B. L., Moser, B., Stock, W., Gallagher, R. E., Willman, C. L., Stone, R. M., Rowe, J. M., Coutre, S., Feusner, J. H., Gregory, J., et al. (2010) · Blood · doi:10.1182/blood-2010-02-269621 · Cited by 382
Self-citationRavandi, F., Estey, E., Jones, D., Faderl, S., O'Brien, S., Fiorentino, J., Pierce, S., Blamble, D., Estrov, Z., Wierda, W., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.6130 · Cited by 376
Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation
Nasr, R., Guillemin, M.-C., Ferhi, O., Soilihi, H., Peres, L., Berthier, C., Rousselot, P., Robledo-Sarmiento, M., Lallemand-Breitenbach, V., Gourmel, B., et al. (2008) · Nature Medicine · doi:10.1038/nm.1891 · Cited by 354
Licht, J., Chomienne, C., Goy, A., Chen, A., Scott, A., Head, D., Michaux, J., Wu, Y., DeBlasio, A., & Miller, W. J. (1995) · Blood · doi:10.1182/blood.v85.4.1083.bloodjournal8541083 · Cited by 343
Acute Promyelocytic Leukemia: Results of Treatment by Daunorubicin
Bernard, J., Weil, M., Boiron, M., Jacquillat, C., Flandrin, G., & Gemon, M.-F. (1973) · Blood · doi:10.1182/blood.v41.4.489.489 · Cited by 338
Lo-Coco, F., Avvisati, G., Vignetti, M., Breccia, M., Gallo, E., Rambaldi, A., Paoloni, F., Fioritoni, G., Ferrara, F., Specchia, G., et al. (2010) · Blood · doi:10.1182/blood-2010-03-276196 · Cited by 332
Iland, H. J., Bradstock, K., Supple, S. G., Catalano, A., Collins, M., Hertzberg, M., Browett, P., Grigg, A., Firkin, F., Hugman, A., et al. (2012) · Blood · doi:10.1182/blood-2012-02-410746 · Cited by 329
Sanz, M. A., Montesinos, P., Rayón, C., Holowiecka, A., de la Serna, J., Milone, G., de Lisa, E., Brunet, S., Rubio, V., Ribera, J. M., et al. (2010) · Blood · doi:10.1182/blood-2010-01-266007 · Cited by 328
HILLESTAD, L. K. (1957) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1957.tb00124.x · Cited by 322
How I treat acute promyelocytic leukemia
Tallman, M. S., & Altman, J. K. (2009) · Blood · doi:10.1182/blood-2009-07-216457 · Cited by 284
Self-citationZheng, P.-Z., Wang, K.-K., Zhang, Q.-Y., Huang, Q.-H., Du, Y.-Z., Zhang, Q.-H., Xiao, D.-K., Shen, S.-H., Imbeaud, S., Eveno, E., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502825102 · Cited by 256
Avvisati, G., Lo Coco, F., Diverio, D., Falda, M., Ferrara, F., Lazzarino, M., Russo, D., Petti, M., & Mandelli, F. (1996) · Blood · doi:10.1182/blood.v88.4.1390.bloodjournal8841390 · Cited by 244
Lo-Coco, F. (2004) · Blood · doi:10.1182/blood-2004-04-1550 · Cited by 225
Kantarjian, H. M., Keating, M. J., Walters, R. S., Estey, E. H., McCredie, K. B., Smith, T. L., Dalton, W. T., Cork, A., Trujillo, J. M., & Freireich, E. J. (1986) · The American Journal of Medicine · doi:10.1016/0002-9343(86)90617-0 · Cited by 215
Tobita, T., Takeshita, A., Kitamura, K., Ohnishi, K., Yanagi, M., Hiraoka, A., Karasuno, T., Takeuchi, M., Miyawaki, S., Ueda, R., et al. (1997) · Blood · doi:10.1182/blood.v90.3.967 · Cited by 198
Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital
Cunningham, I., Gee, T., Reich, L., Kempin, S., Naval, A., & Clarkson, B. (1989) · Blood · doi:10.1182/blood.v73.5.1116.1116 · Cited by 196
Zhu, H.-H., Wu, D.-P., Jin, J., Li, J.-Y., Ma, J., Wang, J.-X., Jiang, H., Chen, S.-J., & Huang, X.-J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.8312 · Cited by 181
Adès, L., Chevret, S., Raffoux, E., de Botton, S., Guerci, A., Pigneux, A., Stoppa, A. M., Lamy, T., Rigal-Huguet, F., Vekhoff, A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1596 · Cited by 169
Giannı̀, M., Koken, M. H. M., Chelbi-Alix, M. K., Benoit, G., Lanotte, M., Chen, Z., & de Thé, H. (1998) · Blood · doi:10.1182/blood.v91.11.4300 · Cited by 164
Lengfelder, E., Reichert, A., Schoch, C., Haase, D., Haferlach, T., Löffler, H., Staib, P., Heyll, A., Seifarth, W., Saussele, S., et al. (2000) · Leukemia · doi:10.1038/sj.leu.2401843 · Cited by 162
dos Santos, G. A., Kats, L. M., & Pandolfi, P. P. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20131121 · Cited by 152
Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia
Head, D., Kopecky, K., Weick, J. K., et al. (1995) · Blood · doi:10.1182/blood.v86.5.1717.bloodjournal8651717 · Cited by 139
Acute promyelocytic leukemia in 57 previously untreated patients
Cordonnier, C., Vernant, J. P., Brun, B., Heilmann, M. G., Kuentz, M., Bierling, P., Farcet, J., Rodet, M., Duedari, N., Imbert, M., et al. (1985) · Cancer · doi:10.1002/1097-0142(19850101)55:1<18::aid-cncr2820550104>3.0.co;2-b · Cited by 135
Resistance to Arsenic Therapy in Acute Promyelocytic Leukemia
Zhu, H., Qin, Y.-Z., & Huang, X. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1316382 · Cited by 126
Evidence for a Kπ = 1/2+ isomer in neutron-rich 185Ta
Shizuma, T., Ishii, T., Makii, H., Hayakawa, T., Shigematsu, S., Matsuda, M., Ideguchi, E., Zheng, Y., Liu, M., & Morikawa, T. (2007) · The European Physical Journal A · doi:10.1140/epja/i2007-10484-4 · Cited by 126
Latagliata, R., Petti, M. C., Fenu, S., Mancini, M., Spiriti, M. A. A., Breccia, M., Brunetti, G. A., Avvisati, G., Lo‐Coco, F., & Mandelli, F. (2002) · Blood · doi:10.1182/blood.v99.3.822 · Cited by 123
Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia
Au, W., Kumana, C. R., Kou, M., Mak, R., Chan, G., Lam, C., & Kwong, Y. (2003) · Blood · doi:10.1182/blood-2003-01-0298 · Cited by 113
Gemtuzumab Ozogamicin: Time to Resurrect?
Ravandi, F., Estey, E. H., Appelbaum, F. R., Lo‐Coco, F., Schiffer, C. A., Larson, R. A., Burnett, A. K., & Kantarjian, H. M. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.0132 · Cited by 104
Au, W., Kumana, C. R., Lee, H. K. K., Lin, S., Liu, H., Yeung, D. Y. M., Lau, J. S. M., & Kwong, Y. (2011) · Blood · doi:10.1182/blood-2011-05-354530 · Cited by 101
Yanada, M., Tsuzuki, M., Fujita, H., Fujimaki, K., Fujisawa, S., Sunami, K., Taniwaki, M., Ohwada, A., Tsuboi, K., Maeda, A., et al. (2013) · Blood · doi:10.1182/blood-2012-11-466862 · Cited by 78
Efficace, F., Mandelli, F., Avvisati, G., Cottone, F., Ferrara, F., Bona, E. D., Specchia, G., Breccia, M., Levis, A., Sica, S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.3453 · Cited by 78
Siu, C., Au, W., Yung, C., Kumana, C. R., Lau, C., Kwong, Y., & Tse, H. (2006) · Blood · doi:10.1182/blood-2006-01-0054 · Cited by 75
de Botton, S., Chevret, S., Coiteux, V., Dombret, H., Sanz, M. Á., Miguel, J. F. S., Caillot, D., Vekhoff, A., Gardembas, M., Stamatoulas, A., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2402807 · Cited by 71
Chakrabarty, J. L. H., Rubinger, M., Le‐Rademacher, J. G., Wang, H., Grigg, A., Selby, G. B., Szer, J., Rowe, J. M., Weisdorf, D. J., & Tallman, M. S. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.03.025 · Cited by 70
Self-citation[Acute promyelocytic leukemia: retrospective study of 119 patients treated with daunorubicin].
Marty, M. E., Ganem, G., Fischer, J., Flandrin, G., Berger, R., Schaison, G., Degos, L., & Boiron, M. (1984) · PubMed · Cited by 62
Shinagawa, K., Yanada, M., Sakura, T., Ueda, Y., Sawa, M., Miyatake, J., Dobashi, N., Kojima, M., Hatta, Y., Emi, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.3570 · Cited by 59
Hashimoto, Y., Kagechika, H., Kawachi, E., Fukasawa, H., Saito, G., & Shudo, K. (1995) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01218530 · Cited by 42
Pellicori, P., Calicchia, A., Lo‐Coco, F., Cimino, G. G., & Torromeo, C. (2012) · Congestive Heart Failure · doi:10.1111/j.1751-7133.2011.00278.x · Cited by 38
Micol, J., Raffoux, E., Boissel, N., Lengliné, É., Canet, E., Daniel, M., de Labarthe, A., Maarek, O., Cassinat, B., Adès, L., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.11.023 · Cited by 31
Rashidi, A., Riley, M., Goldin, T. A., Sayedian, F. H., Bayerl, M. G., Aguilera, N. S. I., Vos, J. A., Goudar, R. K., & Fisher, S. I. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.06.011 · Cited by 29
Eghtedar, A., Rodríguez, I., Kantarjian, H. M., O'Brien, S. M., Daver, N. G., Garcia‐Manero, G., Ferrajoli, A., Kadia, T. M., Pierce, S. A., Cortes, J. E., et al. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.953143 · Cited by 28
The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission
Muchtar, E., Vidal, L., Ram, R., Gafter‐Gvili, A., Shpilberg, O., & Raanani, P. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009594.pub2 · Cited by 25
Lou, Y., Suo, S., Tong, Y., Tong, H., Qian, W., Meng, H., Mai, W., Huang, J., Yu, W., & Jin, J. (2014) · Annals of Hematology · doi:10.1007/s00277-013-2000-1 · Cited by 15
All-trans-retinoic acid increases cytotoxicity of 1-β-d-arabinofuranosylcytosine in NB4 cells
Flanagan, S. A., & Meckling, K. A. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-002-0561-0 · Cited by 14
Zeidan, A. M., & Gore, S. D. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2725 · Cited by 13
Mannis, G. N., Logan, A. C., Leavitt, A. D., Yanada, M., Hwang, J. H., Olin, R. L., Damon, L. E., Andreadis, C. B., Ai, W. Z., Gaensler, K. M. L., et al. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.201 · Cited by 12
Optimal approach for high-risk acute promyelocytic leukemia
Iland, H. J., Seymour, J. F., & Wei, A. H. (2013) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000025 · Cited by 11
Cited by
IDH mutations in cancer and progress toward development of targeted therapeutics
Dang, L., Yen, K., & Attar, E. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw013 · Cited by 509
Nowell, C. S., & Radtke, F. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.145 · Cited by 369
Li, S., Chen, L., Jin, W., Ma, X., Ma, Y., Dong, F., Zhu, H., Li, J., & Wang, K. (2017) · Scientific Reports · doi:10.1038/s41598-017-18278-x · Cited by 68
Engaging plasticity: Differentiation therapy in solid tumors
Bar-Hai, N., & Ishay-Ronen, D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.944773 · Cited by 35
Metadata
- Authors
- Coombs, C. C., Tavakkoli, M., & Tallman, M. S.
- Venue
- Blood Cancer Journal
- Published
- 2015-04-17
- Volume
- 5
- Issue
- 4
- Pages
- e304-e304
- ISSN
- 2044-5385 (ISSN-L)
- OpenAlex
- W2047008143
- Cited by
- 280
- References
- 66
- FWCI
- 13.38
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.